title: Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
abstract: A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg(-1), capecitabine 1300 mg m(-2) daily for 2 weeks and gemcitabine 1000 mg m(-2) weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%).
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. mjavle@mdanderson.org
authors.forename: M
authors.initials: M
authors.lastname: Javle
authors.forename: J
authors.initials: J
authors.lastname: Yu
authors.forename: C
authors.initials: C
authors.lastname: Garrett
authors.forename: A
authors.initials: A
authors.lastname: Pande
authors.forename: B
authors.initials: B
authors.lastname: Kuvshinoff
authors.forename: A
authors.initials: A
authors.lastname: Litwin
authors.forename: J
authors.initials: J
authors.lastname: Phelan
authors.forename: J
authors.initials: J
authors.lastname: Gibbs
authors.forename: R
authors.initials: R
authors.lastname: Iyer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil; D000093542:Gemcitabine